Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Genzyme Corp.

Data from Genzyme Corp.'s Phase III study of

Thyrogen

recombinant thyroid stimulating hormone provoked divergent interpretations among analysts.

Meirav Chovav of Salomon Brothers said that based on the data (see

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE